Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
Purpose: The purpose of our study is to report our experience with the use of certolizumab pegol in patients with refractory non-infectious uveitis. Observations: We present a case series of three patients with non-infectious uveitis, treated with twice-monthly subcutaneous certolizumab pegol. All o...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993618301336 |